| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2005;36:1295.)
© 2005 American Heart Association, Inc.
Research Reports |
From the Tavistock Intensive Care Unit (A.P.), The National Hospital for Neurology and Neurosurgery, and Department of Neuroimmunology, Institute of Neurology, Queen Square, London, UK; the Department of Neuroimmunology (G.K.), Institute of Neurology, Queen Square, London, UK; and the Colour and Vision Research Laboratories (T.L.S.; http://cvrl.ioo.ucl.ac.uk/index.htm), Institute of Ophthalmology, London, UK.
Correspondence to Dr Axel Petzold, the Department of Neuroimmunology, Institute of Neurology, Queen Square, London WC1N 3BG, UK. E-mail a.petzold{at}ion.ucl.ac.uk
| Abstract |
|---|
|
|
|---|
Methods Colorimetric and spectrophotometric analysis of CSF samples for recognizing the presence of bilirubin either in low concentrations or in the presence of hemolysed blood.
Results The experiments provide the physiological and colorimetric basis for abandoning visual assessment of CSF for xanthochromia.
Conclusion We strongly recommend relying on spectrophotometry as the analytical method of choice.
Key Words: cerebrospinal fluid intracerebral hemorrhage subarachnoid hemorrhage
| Introduction |
|---|
|
|
|---|
The presence of pigments in CSF alters its visual appearance. Oxyhemoglobin makes it appear red or orange, whereas bilirubin gives the yellow coloration of true xanthochromia. Oxyhemoglobin arises both from a traumatic tap and a true subarachnoid hemorrhage. Importantly, the conversion of oxyhemoglobin to bilirubin can only happen in vivo, allowing distinction between a true intracranial bleed and one caused by a traumatic tap. Here, we provide physiological evidence that the commonly practiced3,4 visual assessment of CSF should be abandoned and replaced by spectrophotometry.
| Materials and Methods |
|---|
|
|
|---|
|
All tubes were examined visually for xanthochromia, in normal daylight or cool white fluorescent light, the typical viewing conditions, by 11 analysts, comprising clinical scientists, biomedical scientists, or clinical neurology staff within the Department of Neuroimmunology at National Hospital for Neurology and Neurosurgery. The tubes were presented in a random order and the analysts were naive to their actual concentrations.
Once the visual assessments were complete, all samples were scanned between 350 and 740 nm using an Ultrospec 4300 pro (Amersham Biosciences). The same analysts were then asked to indicate whether bilirubin was present or absent in the scan. The proportions of subjects finding a positive result by visual or spectroscopic assessment were compared using a
2 test.
Finally, the xy chromaticity coordinates of the spectrophotometric scans were calculated according to the standard procedures of specification for visual assessment established by the Commission Internationale de lEclairage (CIE, the International Commission on Illumination). This involves multiplying the spectral transmittances of the samples, converted from their optical densities, by the spectral concentration of the radiant power of the source illuminating them and then multiplying the product by each of the 3 color-matching functions, which define the CIE standard colorimetric observer.5 The resulting xy chromaticity coordinates of the samples can then be plotted in the CIE 1931 chromaticity diagram for the standard 2° field of view (Figure 1A and 1B), and their dominant wavelengths, which correspond to hue, and excitation purities, which correspond to saturation, can be geometrically calculated (see explanations in the Table and Figure legends and values in Table). The calculations were made for 2 CIE illumination or lighting standards: "D65," which equates to average daylight; and "A," which is for tungsten light.
|
| Results |
|---|
|
|
|---|
A significantly higher proportion of the analysts detected traces of bilirubin spectrophotometrically than visually, both when the xanthochromic CSF samples were contaminated by the presence of hemolyzed blood (series A) and when they were desaturated (series B). In series A, visual detection failed for CSF samples with dominant wavelengths >574 nm (samples A1 to A7), most of which fall considerably outside the color category "pure yellow." In series B, bilirubin could not be reliably detected in CSF specimens with excitation purity levels <2.4% (samples B5 to B8). In contrast, in both series A and B, bilirubin could be reliably detected in all the samples by examining the spectrophotometric scans.
This study confirms that spectrophotometry is superior to color vision for analyzing CSF samples for the presence of bilirubin.7 Most critical CSF samples are either contaminated by oxyhemoglobin or have only low levels of bilirubin. Under such conditions, detection of xanthochromia becomes unreliable, especially when viewed under incandescent lighting or a tungsten desk lamp (corresponding to CIE standard illuminant A). A lower proportion of the assessors were able to detect xanthochromia for samples B4 (7/11,
2=4.88, P<0.05), B5 (3/11,
2=9.21, P<0.01), and B6 (0/11,
2=6.47, P=0.01; see insets in Figure 1B) under tungsten light than under daylight conditions. Colorimetric analysis revealed that all of the samples now fell completely outside the "pure yellow" category. This condition represents a "worst-case scenario," such as may be encountered during a night on-call.
| Discussion |
|---|
|
|
|---|
Approximately 80% of all CSF samples with significant amounts of bilirubin appear rather "red" than "yellow,"8 but 99.7% of >3500 laboratories participating in 2 recent American surveys3,4 still assess samples by color vision. The observations presented here provide a physiological basis for abandoning the visual assessment of CSF for xanthochromia and rely on spectrophotometry instead.9
| Acknowledgments |
|---|
Received January 7, 2005; accepted February 25, 2005.
| References |
|---|
|
|
|---|
2. Vermeulen M, Hasan D, et al. The time course of aneurysmal haemorrhage on computed tomograms. J Neurol Neurosurg Psych. 1989; 52: 826828.
3. Edlow JA, Bruner KS, Horowitz GL. Xanthochromia. Arch Pathol Lab Med. 2002; 126: 413415.[Medline] [Order article via Infotrieve]
4. Judge B. Laboratory Analysis of Xanthochromia in Patients With Suspected Subarachnoidal Hemorrhage: A National Survey. Philadelphia: Scientific Assembly, American College of Emergency Physicians; 2000.
5. Wyszecki G, Stiles WS. Color Science: Concepts and Methods, Quantitative Data and Formulae, 2nd ed. New York: John Wiley & Sons; 2000.
6. Petzold A, Sharpe LT. Hue memory and discrimination in young children. Vision Res. 1998; 38: 37593772.[CrossRef][Medline] [Order article via Infotrieve]
7. Marden NA, Thomas PH, Stansbie D. Is the naked eye as sensitive as the spectrophotometer for detecting xanthochromia in cerebrovascular disease? In: Martin SM, ed. Proceedings of the National Meeting, 2001 April 30May 4, London. London: Association of Clinical Biochemists, 2001: 53.
8. Petzold A, Keir G, Sharpe LT. Spectralphotometry for xanthochromia. N Eng J Med. 2004; 351: 16951696.
9. UK NEQAS For Immunochemistry Working Group. National guidelines for analysis of cerebrospinal fluid for bilirubin in suspected subarachnoid haemorrhage. Ann Clin Biochem. 2003; 40: 481488.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
L. E. Nigrovic, M. Trivedi, J. A. Edlow, and M. I. Neuman Cerebrospinal Fluid Xanthochromia in Newborns Is Related to Maternal Labor Before Delivery Pediatrics, November 1, 2007; 120(5): e1212 - e1216. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Perry, M. L.A. Sivilotti, I. G. Stiell, G. A. Wells, J. Raymond, M. Mortensen, and C. Symington Should Spectrophotometry Be Used to Identify Xanthochromia in the Cerebrospinal Fluid of Alert Patients Suspected of Having Subarachnoid Hemorrhage? Stroke, October 1, 2006; 37(10): 2467 - 2472. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |